- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Reneo Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.03. | Reneo Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.03. | Reneo Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.03. | Reneo Pharmaceuticals GAAP EPS of -$2.52 | 1 | Seeking Alpha | ||
| 28.03. | Reneo Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 28.03. | Reneo Pharmaceuticals: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 28.03. | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update | 115 | GlobeNewswire (Europe) | IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for... ► Artikel lesen | |
| 23.02. | Reneo Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.12.23 | Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session | 2 | Benzinga.com | ||
| 27.12.23 | US STOCKS Reneo Pharma, Cytokinetics, Burford Capital | 19 | Reuters | ||
| 27.12.23 | Reneo Pharma rises on Concerta's $60 million acquisition offer | 3 | Reuters | ||
| 26.12.23 | Reneo Pharma up on acquisition offer from Concentra Biosciences | 4 | Reuters | ||
| 15.12.23 | Reneo cuts 70% of staff following Phase III trial failure | 1 | Pharmaceutical Technology | ||
| 15.12.23 | Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study | 2 | Zacks | ||
| 15.12.23 | 5 Analysts Have This to Say About Reneo Pharmaceuticals | 2 | Benzinga.com | ||
| 14.12.23 | Reneo stock plunges 84% as company shuts down lead program | 8 | Seeking Alpha | ||
| 14.12.23 | Reneo pulls plug on only asset after phase 2b fail, sending 70% of staff out the door and stock plummeting | 2 | FierceBiotech | ||
| 14.12.23 | Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today? | 5 | Benzinga.com | ||
| 14.12.23 | Reneo Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.12.23 | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) | 289 | GlobeNewswire (Europe) | The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE)... ► Artikel lesen |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,565 | -0,39 % | Pfizer - mit Seagan soll die Wende kommen | ||
| INNOCAN PHARMA | 0,195 | +7,14 % | Jetzt im Blickpunkt: Biotech-Perle kurz vor entscheidender Meilenstein-Meldung! | ||
| ASTRIA THERAPEUTICS | 9,250 | +0,54 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 12,400 | -0,40 % | Assembly Biosciences: CEO begeistert von "außergewöhnlichen Fortschritten" | Zusammen mit der Einladung zur Hauptversammlung am 29. Mai präsentierte Assembly Biosciences (WKN: A402CB) gestern seinen aktuellen Geschäftsbericht im Hochglanz-Format. In einem Anschreiben an Aktionäre... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 1,317 | +3,38 % | NEKTAR THERAPEUTICS - 8-K, Current Report | ||
| SOLIGENIX | 0,400 | -3,22 % | SOLIGENIX, INC. - 8-K, Current Report | ||
| TALPHERA | 0,856 | -6,65 % | TALPHERA, INC. - 8-K, Current Report | ||
| ROCKET LAB USA | 3,480 | +3,42 % | How Rocket Lab Outgrew Billionaire Elon Musk's Space Company in Q1 | ||
| NEUROGENE | 31,170 | +2,10 % | Neurogene Inc. - 8-K, Current Report | ||
| BOIRON | 33,600 | -1,32 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,170 | +1,70 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis | - ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports "Soft" Topical JAK Inhibitor Approach - - ATI-1777... ► Artikel lesen | |
| MEDICINOVA | 1,250 | 0,00 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 6,400 | -1,69 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| SOLID BIOSCIENCES | 9,100 | +2,82 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
| HARROW | 10,320 | -4,27 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen |
RENEO PHARMACEUTICALS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,670 Euro und damit -3,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
